Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

BridgeBio Pharma Assets & Liabilities Overview 2018-2023 | BBIO

BridgeBio Pharma assets & liabilities overview from 2018 to 2023. Assets & liabilities overview can be defined as overview of the balance sheet showing the primary categories of assets, liabilities and equity in a single chart.
  
BridgeBio Pharma Annual Assets & Liabilities Overview
(Millions of US $)
BridgeBio Pharma Quarterly Assets & Liabilities Overview
(Millions of US $)
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.656B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $15.482B 5.59
Dr Reddy's Laboratories (RDY) India $12.441B 19.67
Aspen Pharmacare (APNHY) South Africa $5.038B 0.00
Bausch Health Cos (BHC) Canada $3.183B 2.48
Amphastar Pharmaceuticals (AMPH) United States $2.009B 13.75
Supernus Pharmaceuticals (SUPN) United States $1.646B 0.00
Taysha Gene Therapies (TSHA) United States $0.447B 0.00
Generation Bio (GBIO) United States $0.193B 0.00
Assembly Biosciences (ASMB) United States $0.069B 0.00
Personalis (PSNL) United States $0.064B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00